|Day Low/High||197.98 / 202.53|
|52 Wk Low/High||163.31 / 210.19|
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
They continue to work in this market and we believe can drive growth longer-term.
We have received a number of updates from analysts on the JP Morgan healthcare conference.
EVENITY Approved to Reduce the Risk of Fractures and Increase Bone Mineral Density in Men and Postmenopausal Women With Osteoporosis at High Risk of Fracture
After the very negative market environment the past few months it is refreshing and exciting to find a stock with some upside potential.
Plus, oil is up and portfolio name Danaher makes a positive pre-announcement.
Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
The Repatha Pre-Filled Syringe and Repatha Pushtronex® System are Now Available at a Reduced List Price of $5,850
It was a rough day for U.S. equity markets as the Dow plunged 660 points.
Jim discusses Thursday's market selloff, what Apple's preannouncement means for the stock long term, the announced Bristol-Myers Squibb acquisition of Celgene and how it relates to Amgen, the oil market, and much more!
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
The health care sector may a good place to weather this storm. Here is why and how to play it.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
We believe the potential of a trade deal has increased in recent weeks so we are hesitant to sell into its strength.
ABBV offers an ideal mix of growth, value and income.
Markets remain treacherous as investors are becoming increasingly concerned about a number of factors.
If we see downside being priced in, that creates the opporunity to buy.
Jim discusses the Fed decision to raise interest rates and its impact on the markets, what stocks/sectors he is interested in for 2019, and a number of Portfolio names.
Application Seeks to Include Adult Patients who Have had Immune Thrombocytopenia for 12 Months or Less
Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen's Oncology Assets, Including BiTE® Molecules
Amgen Golden Tickets Provide Startup Companies With Free Lab Space to Further Advance Innovative Science and Technology
- Q3 share repurchases increase 57.7% year over year to a record $203.8 billion
Filing for ABP 710, a Biosimilar Candidate to Infliximab, Supported by Phase 3 Study in Patients With Moderate-to-Severe Rheumatoid Arthritis
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.